A Post Marketing Evaluation of the Effectiveness of FluMist Risk Minimization Plan in Children
A Post Marketing Evaluation of the Effectiveness of the Risk Minimization Plan For Use of FluMist Among Children Less Than 5 Years of Age
Przegląd badań
Status
Status
Warunki
Warunki
Interwencja / Leczenie
Interwencja / Leczenie
Szczegółowy opis
To evaluate the rate of FluMist administration compared to other influenza vaccine use in the following pediatric populations:
- Children younger than 24 months of age
- Children 24-59 months of age with a claim associated with a diagnosis of asthma
- Children 24-59 months of age without a claim associated with a diagnosis of asthma, but with dispensed medication for wheezing
- Children 24-59 months of age with immunosuppression
- To describe, in children in the above populations who receive FluMist, the type and number of Emergency Room visits or hospitalizations associated with an insurance claim within 42 days of receiving FluMist
- To explore the rationale for FluMist immunization of pediatric populations that are excluded from recommended usage by characterizing the use in these populations
Typ studiów
Typ studiów
Zapisy (Rzeczywisty)
Zapisy
Kontakty i lokalizacje
Lokalizacje studiów
-
-
North Carolina
-
Research Triangle, North Carolina, Stany Zjednoczone
- Research Site
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Kryteria kwalifikacji
Wiek uprawniający do nauki
- Dziecko
- Dorosły
- Starszy dorosły
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Metoda próbkowania
Badana populacja
Opis
- Children less than 24 months of age during August through January/February.
Children <24 to 59 months of age during August through January/February, with:
- two outpatient claims for asthma, or
- one inpatient/emergency room claim for asthma, or
- one outpatient claim for asthma and at least one SABA prescription during a defined 12-month period.
- Children <24 to 59 months of age during August through January/February, without any claims associated with a diagnosis of asthma, but with at least one dispensing for SABA, as indicated by pharmacy claims during a defined 12-month period.
- Children 24 to 59 months of age during August to January/February with evidence of immunosuppression prior to the date of influenza vaccination based on available medical and pharmacy claims.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Modele obserwacyjne: Kohorta
- Perspektywy czasowe: Z mocą wsteczną
Liczba grup / kohort
Kohorty i interwencje
Grupa / KohortaGrupa / Kohorta |
Interwencja / LeczenieInterwencja / Leczenie |
|---|---|
|
1
Children less than 24 months of age
|
There were no interventions.
No subjects were enrolled in this retrospective database study.
|
|
2
Children 24 to 59 months of age with a claim associated with a diagnosis of asthma
|
There were no interventions.
No subjects were enrolled in this retrospective database study.
|
|
3
Children 24 to 59 months of age without a claim associated with a diagnosis of asthma, but with dispensed medication for wheezing
|
There were no interventions.
No subjects were enrolled in this retrospective database study.
|
|
4
Children 24-59 months of age with immunosuppression
|
There were no interventions.
No subjects were enrolled in this retrospective database study.
|
Co mierzy badanie?
Podstawowe miary wyniku
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
FluMist Use in Participants up to 59 Months of Age
Ramy czasowe: 2009-2010
|
Among participants up to 59 months of age who received any flu vaccine, number who received FluMist
|
2009-2010
|
|
Vaccinating Physician Specialty: Pediatrician or Pediatric Specialist
Ramy czasowe: 2009-2010
|
Specialty of vaccinating physician who provided FluMist.
|
2009-2010
|
|
Vaccinating Physician Specialty: General/Family Practitioner
Ramy czasowe: 2009-2010
|
Specialty of vaccinating physician who provided FluMist
|
2009-2010
|
|
Vaccinating Physician Specialty: Other
Ramy czasowe: 2009-2010
|
Specialty of vaccinating physician who provided FluMist
|
2009-2010
|
|
Vaccinating Physician Specialty: Unknown
Ramy czasowe: 2009-2010
|
Specialty of vaccinating physician who provided FluMist
|
2009-2010
|
|
Geographic Region: Northeastern
Ramy czasowe: 2009-2010
|
Geographic region of parents' residence among participants receiving FluMist
|
2009-2010
|
|
Geographic Region: North Central
Ramy czasowe: 2009-2010
|
Geographic region of parents' residence among participants receiving FluMist
|
2009-2010
|
|
Geographic Region: Southern
Ramy czasowe: 2009-2010
|
Geographic region of parents' residence among participants receiving FluMist
|
2009-2010
|
|
Geographic Region: Western
Ramy czasowe: 2009-2010
|
Geographic region of parents' residence among participants receiving FluMist
|
2009-2010
|
|
Number of Outpatient Visits: 0
Ramy czasowe: 2009-2010
|
Among participants vaccinated with FluMist, the number who had 0 outpatient visits in the 3 months prior to vaccination
|
2009-2010
|
|
Number of Outpatient Visits: 1
Ramy czasowe: 2009-2010
|
Among participants vaccinated with FluMist, the number who had 1 outpatient visit in the 3 months prior to vaccination
|
2009-2010
|
|
Number of Outpatient Visits: 2 or More
Ramy czasowe: 2009-2010
|
Among participants vaccinated with FluMist, the number who had 2 or more outpatient visits in the 3 months prior to vaccination
|
2009-2010
|
|
Number of Days With a Respiratory Claim in 28 Days Prior to Vaccination: 0
Ramy czasowe: 2009-2010
|
Among participants vaccinated with FluMist, the number of days with a respiratory claim (asthma, acute respiratory distress, bronchospasm, influenza, respiratory syncytial virus, bronchiolitis, bronchitis, pneumonia, croup, sinusitis, adenovirus infection, coxsackie virus infection, rhinovirus infection, nasopharyngitis, laryngitis and tracheitis, upper respiratory infection, cough) in the 28 days prior to vaccination.
|
2009-2010
|
|
Number of Days With a Respiratory Claim in 28 Days Prior to Vaccination: 1
Ramy czasowe: 2009-2010
|
Among participants vaccinated with FluMist, the number of days with a respiratory claim (asthma, acute respiratory distress, bronchospasm, influenza, respiratory syncytial virus, bronchiolitis, bronchitis, pneumonia, croup, sinusitis, adenovirus infection, coxsackie virus infection, rhinovirus infection, nasopharyngitis, laryngitis and tracheitis, upper respiratory infection, cough) in the 28 days prior to vaccination.
|
2009-2010
|
|
Number of Days With a Respiratory Claim in 28 Days Prior to Vaccination: 2 or More
Ramy czasowe: 2009-2010
|
Among participants vaccinated with FluMist, the number of days with a respiratory claim (asthma, acute respiratory distress, bronchospasm, influenza, respiratory syncytial virus, bronchiolitis, bronchitis, pneumonia, croup, sinusitis, adenovirus infection, coxsackie virus infection, rhinovirus infection, nasopharyngitis, laryngitis and tracheitis, upper respiratory infection, cough) in the 28 days prior to vaccination.
|
2009-2010
|
Współpracownicy i badacze
Sponsor
Sponsor
Współpracownicy
Współpracownicy
Śledczy
Śledczy
- Dyrektor Studium: Chris Ambrose, M.D., MedImmune LLC
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów
Rozpoczęcie studiów
Zakończenie podstawowe (Rzeczywisty)
Zakończenie podstawowe
Ukończenie studiów (Rzeczywisty)
Ukończenie studiów
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Oszacować)
Pierwszy wysłany
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Oszacować)
Ostatnia wysłana aktualizacja
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
Inne numery identyfikacyjne badania
- MI-MA175
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .